TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06846710: Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118

Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. · Phase: PHASE1 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 132 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$666,672

Rescue Site Savings

+$438,600

Unlock Full NCT06846710 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06846710 Rescue Dossier →